A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

NCT ID: NCT04055454

Last Updated: 2025-07-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-26
• Study Completion Date: 2021-01-15

Brief Summary

This is a randomized, placebo-controlled, single-center, dose finding phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and an observer-blinded treatment phase.

The aim is to investigate the safety, tolerability and immunogenicity of MV-LASV after administration of two different dose levels of MV-LASV. Placebo will be applied to blind the different Treatment schedules.

Detailed Description

This is a prospective, interventional, observer-blinded, randomized, phase I trial, comparing different dose levels of MV-LASV. As safety precaution, the study will begin with enrollment of two successive unblinded dose groups of sentinel participants randomized into groups of four in an open-label fashion (group A and B).

Thereafter, 52 participants will be enrolled in an observer-blinded, randomized manner into one of the three treatment groups (A, B or C). Placebo will be applied to blind the different Treatment schedules.

After the screening visit, participants will bei enrolled to one of three Treatment groups. Visits for immunogenicity sample collection and safety assessments will be performed for 56 days, and additionally subjects will for long-term follow-up up to 365 days.

The investigator and site personnel assessing Adverse Events (AEs), all participants, as well as the sponsor's representatives involved in the monitoring and conduct of the study will be unblinded to which vaccine was administered within the unblinded treatment phase. Only the site personnel performing randomization, reparation and administration of Investigational Medicinal Product (IMP) will be unblinded within the randomized observer-blinded treatment phase.

Conditions

Lassa Virus Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

MV-LASV low dose: treatment group A

In total 24 participants will receive two low dose treatments with MV-LASV on day 0 and 28.

Group Type: EXPERIMENTAL

MV-LASV

Intervention Type: BIOLOGICAL

The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Placebo

Intervention Type: OTHER

A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.

MV-LASV high dose: treatment group B

In total 24 participants will receive two high dose treatments with MV-LASV on day 0 and 28.

Group Type: EXPERIMENTAL

MV-LASV

Intervention Type: BIOLOGICAL

The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Placebo: treatment group C

In total 12 participants will receive placebo treatment on day 0 and 28.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.

Interventions

MV-LASV

The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.

Intervention Type: BIOLOGICAL

Placebo

A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent obtained before any trial-related activities

2. Healthy men or women aged 18 to ≤ 55 years on the day of consenting

3. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study

4. All female participants of childbearing potential, defined as all woman physiologically capable of becoming pregnant, must have a negative pregnancy test at screening

5. Willingness not to become pregnant or to father a child during the study up to 182 days after the first vaccination by practicing reliable methods of contraception

6. Availability during the duration of the trial

Exclusion Criteria

1. Participation in another investigational clinical study (including exposure to an IMP or device) within four weeks before the screening visit or planned concurrent participation in another clinical study before study completion

2. History of immunodeficiency, known HIV infection or current hepatitis B/C infection

3. History of drug addiction including alcohol dependence within the last two years

4. Inability or unwillingness to avoid intake of more than around 20g alcohol per day during 48 hours after each vaccination

5. Vaccination within four weeks prior to first vaccination or planning to receive any non-study vaccine within 182 days after the first vaccination

6. Prior receipt of any Lassa vaccine

7. Recent infection within one week prior to Screening visit

8. Blood donations including plasma donations, 90 days prior to Screening visit and anticipated blood, plasma, tissue, sperm or organ donation, throughout the study until end of treatment period

9. Clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, inflammatory, autoimmune or neurological diseases or clinically relevant abnormal laboratory values, that in the opinion of the investigator may interfere with the aim of the study

10. History of neoplastic disease (excluding non-melanoma skin cancer that was successfully treated) within the past five years or a history of any hematological malignancy

11. Behavioral, cognitive, or psychiatric condition that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol

12. History of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of allergic reaction likely to be exacerbated by any component of the vaccine

13. History of or present hearing deficit

14. Present thrombocytopenia and/or history of thrombocytopenia and/or bleeding disorders.

15. History of anaphylaxis to drugs or other allergic reactions, which the investigator considers compromising the safety of the volunteer

16. Use of medication during two weeks before the first vaccination and throughout the study, which the investigator considers affecting the validity of the study, except hormonal contraception or hormonal replacement therapy in female participants (prior to taking any medication within 72 hours before study vaccination, the participant should consult the investigator)

17. Use of immunosuppressive drugs like corticosteroids (excluding topical preparations) within 30 days prior to the first vaccination or anticipated use before completion of day 182

18. Receipt of blood products or immunoglobulins within 120 days prior to the Screening Visit or anticipated receipt of any blood product or immunoglobulin before completion of day 182

19. Pregnancy or lactation at screening or planning to become pregnant before completion of day 182

20. Unreliable contraception Methods

21. Persons in a direct relationship with the sponsor, an investigator or other study team members. Direct dependent relationships include close relatives (i.e. children, parents, partner/spouse, siblings) as well as employees of the clinical study site or the sponsor

22. Individuals who are living and/or working with severely immunocompromised people, children under 15 months old or pregnant women

23. Participants who travelled within one year prior to the first vaccination or plan to travel during the study to an endemic country

24. A rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Coalition for Epidemic Preparedness Innovations

OTHER

Sponsor Role: collaborator

Harmony Clinical Research BVBA

OTHER

Sponsor Role: collaborator

Assign Data Management and Biostatistics GmbH

OTHER

Sponsor Role: collaborator

Themis Bioscience GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

University of Antwerpen, Centre for the Evaluation of Vaccination (CEV)

Antwerp, , Belgium

Countries

Belgium

References

Tschismarov R, Van Damme P, Germain C, De Coster I, Mateo M, Reynard S, Journeaux A, Tomberger Y, Withanage K, Haslwanter D, Terler K, Schrauf S, Mullner M, Tauber E, Ramsauer K, Baize S. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet. 2023 Apr 15;401(10384):1267-1276. doi: 10.1016/S0140-6736(23)00048-X. Epub 2023 Mar 16.

Reference Type: RESULT

PMID: 36934733 (View on PubMed)

Other Identifiers

MV-LASV-101

Identifier Type: OTHER

Identifier Source: secondary_id

2018-003647-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

V182-001

Identifier Type: -

Identifier Source: org_study_id